When did INTELLIA THERAPEUTICS INC (NTLA) report earnings last quarter?
INTELLIA THERAPEUTICS INC (NTLA) last reported earnings on 2/26/2026.
NASDAQ:NTLA • US45826J1051
Past quarterly earnings results for INTELLIA THERAPEUTICS INC (NTLA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.83 | -0.97 | 14.78% | 34.65% | 23.017M | 13.042M | 76.48% | 78.79% |
| Q3 2025 | -0.92 | -1.02 | 9.97% | 31.34% | 13.782M | 15.489M | -11.02% | 51.27% |
| Q2 2025 | -0.98 | -1.04 | 5.61% | 35.53% | 14.245M | 12.402M | 14.86% | 104.76% |
| Q1 2025 | -1.10 | -1.31 | 15.91% | 1.79% | 16.627M | 12.111M | 37.29% | -42.54% |
| Q4 2024 | -1.27 | -1.36 | 6.34% | 13.01% | 12.874M | 8.703M | 47.93% | 771.57% |
| Q3 2024 | -1.34 | -1.41 | 5.12% | 2.90% | 9.111M | 8.013M | 13.70% | -24.02% |
| Q2 2024 | -1.52 | -1.26 | -20.94% | -8.57% | 6.957M | 19.545M | -64.41% | -48.82% |
| Q1 2024 | -1.12 | -1.41 | 20.41% | 4.27% | 28.935M | 11.734M | 146.59% | 129.53% |
| Q4 2023 | -1.46 | -1.48 | 1.23% | -4.29% | -1.917M | 13.082M | -114.65% | -114.13% |
| Q3 2023 | -1.38 | -1.53 | 9.73% | 7.38% | 11.992M | 12.697M | -5.55% | -9.63% |
| Q2 2023 | -1.40 | -1.35 | -3.91% | -5.26% | 13.594M | 12.319M | 10.35% | -3.11% |
| Q1 2023 | -1.17 | -1.43 | 18.08% | 40.31% | 12.606M | 12.063M | 4.50% | 12.05% |
| Q4 2022 | -1.40 | -1.42 | 1.45% | -28.44% | 13.57M | 11.558M | 17.41% | 5.60% |
| Q3 2022 | -1.49 | -1.31 | -13.96% | -53.61% | 13.27M | 11.569M | 14.70% | 84.31% |
| Q2 2022 | -1.33 | -1.33 | 0.17% | -31.68% | 14.03M | 9.602M | 46.12% | 114.20% |
| Q1 2022 | -1.96 | -1.13 | -73.90% | -184.06% | 11.25M | 8.715M | 29.09% | 74.42% |
| Q4 2021 | -1.09 | -0.96 | -13.14% | -57.97% | 12.85M | 8.426M | 52.50% | 94.70% |
| Q3 2021 | -0.97 | -0.86 | -12.71% | -106.38% | 7.2M | 8.837M | -18.52% | -67.60% |
| Q2 2021 | -1.01 | -0.65 | -56.35% | -65.57% | 6.55M | 12.128M | -45.99% | -59.72% |
| Q1 2021 | -0.69 | -0.67 | -2.83% | -9.52% | 6.45M | 10.055M | -35.85% | -50.08% |
| Q4 2020 | -0.69 | -0.61 | -12.32% | - | 6.6M | 14.377M | -54.09% | - |
| Q3 2020 | -0.47 | -0.60 | 21.98% | - | 22.22M | 15.896M | 39.78% | - |
| Q2 2020 | -0.61 | -0.70 | 13.41% | - | 16.26M | 8.716M | 86.55% | - |
| Q1 2020 | -0.63 | -0.43 | -45.52% | - | 12.92M | 19.782M | -34.69% | - |
Notes
INTELLIA THERAPEUTICS INC (NTLA) last reported earnings on 2/26/2026.
INTELLIA THERAPEUTICS INC (NTLA) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, INTELLIA THERAPEUTICS INC (NTLA) has beaten EPS estimates in 4 out of 4 releases.